Explanipedia

Durotaxis is a driver and potential therapeutic target in lung fibrosis and metastatic pancreatic cancer Open

Taslim A. Al-Hilal, Maria-Anna Chrysovergi, Paula Grasberger, Fei Liu, Vera Auernheimer , et al. · 2025

Durotaxis, cell migration along stiffness gradients, is linked to embryonic development, tissue repair and disease. Despite solid in vitro evidence, its role in vivo remains largely speculative. Here we demonstrate that durotaxis actively …

A Systematic review of the prevalence of degenerative thoracic spinal pathologies on magnetic resonance imaging in healthy/asymptomatic individuals Open

E. Lowton, A. Rafati-Fard, Eric S. White, Muthanna Jabbar, R. Khanduja , et al. · 2025

Effects of nintedanib on circulating biomarkers of idiopathic pulmonary fibrosis Open

Gisli Jenkins, Vincent Cottin, Yasuhiko Nishioka, Imre Noth, Eric S. White , et al. · 2024

Background Biomarkers that change in response to nintedanib in subjects with idiopathic pulmonary fibrosis (IPF) would be valuable. We investigated the effects of nintedanib on circulating biomarkers in subjects with IPF in the INMARK tria…

Assessing How Patients Feel, Function, and Survive in Idiopathic Pulmonary Fibrosis: The Best Is the Enemy of the Good Open

Susanne Stowasser, Gregory P. Cosgrove, Eric S. White · 2024

Circulating biomarkers and progression of idiopathic pulmonary fibrosis: data from the INMARK trial Open

Toby M. Maher, Gisli Jenkins, Vincent Cottin, Yasuhiko Nishioka, Imre Noth , et al. · 2024

Background We used data from the INMARK trial to investigate associations between circulating biomarkers of extracellular matrix (ECM) turnover, inflammation and epithelial dysfunction and disease progression in subjects with idiopathic pu…

Contents Open

Alexander D. Shapeton, Scott Kinlay, Carl Geahchan, Jamel Ortoleva, William A. Riley , et al. · 2024

The American Thoracic Society Research Program: Twenty Years of Driving Discovery in Respiratory Medicine Open

Kamran Atabai, M. Safwan Badr, J. P. Costello, Karen M. Ridge, Sharon Rounds , et al. · 2024

Three dimensional fibrotic extracellular matrix directs microenvironment fiber remodeling by fibroblasts Open

Mehmet Nizamoglu, Frederique Alleblas, Taco Koster, Theo Borghuis, Judith M. Vonk , et al. · 2024

Idiopathic pulmonary fibrosis (IPF), for which effective treatments are limited, results in excessive and disorganized deposition of aberrant extracellular matrix (ECM). An altered ECM microenvironment is postulated to contribute to diseas…

Cardiac Tamponade in ECMO: Infrequent but Important Open

Siavash Saadat, Amy French, Eric S. White, Jamel Ortoleva · 2024

Lung function trajectories in patients with idiopathic pulmonary fibrosis Open

Megan L. Neely, Anne S. Hellkamp, Shaun Bender, Jamie L. Todd, Timothy Liesching , et al. · 2023

Background Idiopathic pulmonary fibrosis (IPF) is a progressive fibrosing interstitial lung disease characterised by decline in lung function. We evaluated trajectories of forced vital capacity (FVC) and diffusing capacity (DLco) in a coho…

Three dimensional fibrotic extracellular matrix directs microenvironment fiber remodeling by fibroblasts Open

Mehmet Nizamoglu, Frederique Alleblas, Taco Koster, Theo Borghuis, Judith M. Vonk , et al. · 2023

Idiopathic pulmonary fibrosis (IPF), for which effective treatments are limited, results in excessive and disorganized deposition of an aberrant extracellular matrix (ECM). An altered ECM microenvironment is postulated to contribute to dis…

The Effects of the COVID-19 Pandemic on IVC Filter Placement Open

Dylan Schneider, Emily Keltner, Eric S. White · 2023

This project was supported by the Parkview Research Center and the Student Education and Research Fellowship Program.This project was funded, in part, with support from the Indiana Clinical and Translational Sciences Institute funded, in p…

NF-κB drives epithelial-mesenchymal mechanisms of lung fibrosis in a translational lung cell model Open

Patrick Sieber, Anny Schäfer, Raphael Lieberherr, Silvia L. Caimi, Urs Lüthi , et al. · 2022

In the progression phase of idiopathic pulmonary fibrosis (IPF), the normal alveolar structure of the lung is lost and replaced by remodeled fibrotic tissue and by bronchiolized cystic airspaces. Although these are characteristic features …

Genome-wide association study identifies multiple HLA loci for sarcoidosis susceptibility Open

SY Liao, Stefan H. Jacobson, NY Hamzeh, D.A. Culver, BQ Barkes , et al. · 2022

Sarcoidosis is a complex systemic disease. Our study aimed to 1) identify novel alleles associated with sarcoidosis susceptibility; 2) provide an in-depth evaluation of HLA alleles and sarcoidosis susceptibility; 3) integrate genetic and t…

Systemic sclerosis associated interstitial lung disease: a conceptual framework for subclinical, clinical and progressive disease Open

David Roofeh, Kevin M. Brown, Ella A. Kazerooni, Donald P. Tashkin, Shervin Assassi , et al. · 2022

Objectives To establish a framework by which experts define disease subsets in systemic sclerosis associated interstitial lung disease (SSc-ILD). Methods A conceptual framework for subclinical, clinical and progressive ILD was provided to …

Hypothyroidism Is Associated with Increased Mortality in Interstitial Pneumonia with Autoimmune Features Open

David N. O’Dwyer, Bonnie R. Wang, Vivek Nagaraja, Kevin R. Flaherty, Dinesh Khanna , et al. · 2022

"Hypothyroidism Is Associated with Increased Mortality in Interstitial Pneumonia with Autoimmune Features." Annals of the American Thoracic Society, 19(10), pp. 1772–1776

Challenges for Clinical Drug Development in Pulmonary Fibrosis Open

Eric S. White, Matthew J. Thomas, Susanne Stowasser, Kay Tetzlaff · 2022

Pulmonary fibrosis is a pathologic process associated with scarring of the lung interstitium. Interstitial lung diseases (ILDs) encompass a large and heterogenous group of disorders, a number of which are characterized by progressive pulmo…

Disparities in Lung Transplant among Patients with Idiopathic Pulmonary Fibrosis: An Analysis of the IPF-PRO Registry Open

Aparna Swaminathan, Anne S. Hellkamp, Megan L. Neely, Shaun Bender, Luca Paoletti , et al. · 2022

Rationale: Lung transplant offers the potential to extend life for patients with idiopathic pulmonary fibrosis (IPF); yet, this therapeutic modality is only available to a small proportion of patients. Objectives: To identify…

Hospitalizations in patients with idiopathic pulmonary fibrosis Open

Hyun J. Kim, Laurie D. Snyder, Ayodeji Adegunsoye, Megan L. Neely, Shaun Bender , et al. · 2021

Adipose Stromal Cell-Secretome Counteracts Profibrotic Signals From IPF Lung Matrices Open

Gwenda F. Vasse, Lisette van Os, Marina De Jager, Marnix R. Jonker, Theo Borghuis , et al. · 2021

Introduction: Idiopathic pulmonary fibrosis (IPF) is a fibrotic lung disease characterized by excess deposition and altered structure of extracellular matrix (ECM) in the lungs. The fibrotic ECM is paramount in directing resident cells tow…

Detection and Early Referral of Patients With Interstitial Lung Abnormalities Open

Gary M. Hunninghake, Jonathan Goldin, Michel Kadoch, Jonathan A. Kropski, Iván O. Rosas , et al. · 2021

Guidance was established for identifying clinically relevant ILA, subsequent referral, and follow-up. These results lay the foundation for developing practical guidance on managing patients with ILA.

Adoption of Antifibrotic Medications: A Closer Look at the Data Open

Eric S. White, Mona Nili, Sharash Shetty, Thomas B. Leonard · 2021

Post-Hospitalization Mortality in Patients with Idiopathic Pulmonary Fibrosis: Data from the IPF-PRO Registry Open

H.J. Kim, Laurie D. Snyder, Ayodeji Adegunsoye, Megan L. Neely, Shaun Bender , et al. · 2021

Disparities in Lung Transplantation Among Patients with Idiopathic Pulmonary Fibrosis: Data from the IPF-PRO Registry Open

Aparna Swaminathan, Anne S. Hellkamp, Megan L. Neely, Shaun Bender, P. Luca , et al. · 2021

Characteristics of Patients with Idiopathic Pulmonary Fibrosis Admitted to Hospital: Data from the IPF-PRO Registry Open

Mary E. Strek, Laurie D. Snyder, Ayodeji Adegunsoye, Megan L. Neely, Shaun Bender , et al. · 2021

Rationale: Hospitalizations are common among patients with idiopathic pulmonary fibrosis (IPF) and are associated with high mortality.The IPF-PRO Registry is a multicenter, observational registry of patients with IPF in the US.We used data…

Human antigen R promotes lung fibroblast differentiation to myofibroblasts and increases extracellular matrix production Open

Fatmah Al‐Habeeb, Noof Aloufi, Hussein Traboulsi, Xingxing Liu, Parameswaran Nair , et al. · 2021

Idiopathic pulmonary fibrosis (IPF) is a disease of progressive scarring caused by excessive extracellular matrix (ECM) deposition and activation of α‐SMA‐expressing myofibroblasts. Human antigen R (HuR) is an RNA binding protein that prom…

Identification of a unique temporal signature in blood and BAL associated with IPF progression Open

Katy C. Norman, David N. O’Dwyer, Margaret L. Salisbury, Katarina M. DiLillo, Vibha N. Lama , et al. · 2020

Idiopathic pulmonary fibrosis (IPF) is a progressive and heterogeneous interstitial lung disease of unknown origin with a low survival rate. There are few treatment options available due to the fact that mechanisms underlying disease progr…

Type I Collagen Signaling Regulates Opposing Fibrotic Pathways through α<sub>2</sub>β<sub>1</sub> Integrin Open

Manisha Agarwal, Mitchell Goheen, Shijing Jia, Song Ling, Eric S. White , et al. · 2020

Fibrosis is characterized by fibroblast activation, leading to matrix remodeling culminating in a stiff, type I collagen-rich fibrotic matrix. Alveolar epithelial cell (AEC) apoptosis is also a major feature of fibrogenesis, and AEC apopto…

Development and Initial Validation Analyses of the Living with Idiopathic Pulmonary Fibrosis Questionnaire Open

Jeffrey J. Swigris, David Andrae, Tara Churney, Nathan Johnson, Mary Beth Scholand , et al. · 2020

Rationale: Several new drugs for idiopathic pulmonary fibrosis (IPF) are in development. Tools are needed to assess whether these drugs benefit patients on outcomes that matter most to them. Health-related quality of life (HRQL) is …

Gene Expression Profiling in Patients with Idiopathic Pulmonary Fibrosis (IPF) in the INMARK Trial Open

Moisés Selman, Gisli Jenkins, Eric S. White, Vincent Cottin, Yasuhiko Nishioka , et al. · 2020

Eric S. White YOU? Author Swipe